LMO1 Gene Polymorphisms Reduce Neuroblastoma Risk in Eastern Chinese Children: A Three-Center Case-Control Study.

Lili He,Chunlei Zhou,Haixia Zhou,Fei Han,Haiyan Wu,Yizhen Wang,Jinhong Zhu,Jing He,Jincheng Dai,Yingzi Tang

doi:10.3389/fonc.2018.00468

Abstract

Background: Neuroblastoma, a neuroendocrine tumor, stems from the developing sympathetic nervous system. Previous genome-wide association studies (GWASs) have discovered a number of neuroblastoma susceptibility genes in Caucasians including LIM domain only 1 (LMO1).Objective: We conducted a three-center case-control study including 313 cases and 716 controls with the purpose to evaluate the association between five GWAS-identified LMO1 variants (rs110419 A>G, rs4758051 G>A, rs10840002 A>G, rs204938 A>G, and rs2168101 G>T) and neuroblastoma susceptibility in eastern Chinese children.Methods: Odds ratios (ORs) and 95% confidence intervals (CIs) were calculated to evaluate the strength of the associations. False positive report possibility (FPRP) analysis was performed to check whether significant results were noteworthy.Results: Significant associations with neuroblastoma risk were found for four (rs110419, rs4758051, rs10840002, and rs2168101) out of the five polymorphisms. Combined analysis demonstrated that carriers of 4–5 protective genotypes had a significantly decreased risk of neuroblastoma in comparison those with 0–3 protective genotypes (adjusted OR = 0.51, 95% CI = 0.39–0.68, P < 0.0001). Haplotype analysis of the five SNPs yield four significant haplotypes associated with neuroblastoma susceptibility.Conclusion: In conclusion, we confirmed LMO1 polymorphisms may reduce neuroblastoma risk in eastern Chinese populations.

Highlights

Neuroblastoma is the most frequently diagnosed solid tumor outside of cranium in childhood, especially in the first year of life [1,2,3]
A total of 313 cases and 762 controls were recruited for this association study (Table 1)
Case and controls were subjected to frequency matching to ensure there was no significant difference in the age (P = 0.823) and gender

Summary

Introduction

Neuroblastoma is the most frequently diagnosed solid tumor outside of cranium in childhood, especially in the first year of life [1,2,3]. A median age at diagnosis of this disease is about 17 months. Neuroblastoma is a type of neuroendocrine tumor, originating from the developing sympathetic nervous system. Neuroblastoma is a group of LMO1 Polymorphisms Reduce Neuroblastoma Risk heterogeneous diseases. Neuroblastoma patients are traditionally categorized into low, intermediate-, and high-risk groups. To more accurately group patients, the International Neuroblastoma Risk Group (INRG) classification has yield 16 risk groups, by integrating clinical and molecular characteristics, such as age at diagnosis, tumor stage, histopathology, as well as genetic signatures [6]. Environmental factors for neuroblastoma are not wellestablished Environmental exposures, such as exposures to drugs and hair dyes during maternity and pregnancy, may increase the risk of the disease, to a small extent [7]. Neuroblastoma, a neuroendocrine tumor, stems from the developing sympathetic nervous system. Previous genome-wide association studies (GWASs) have discovered a number of neuroblastoma susceptibility genes in Caucasians including LIM domain only 1 (LMO1)

Methods

Results

Conclusion